| Literature DB >> 27071615 |
Yun-Jung Lee1, Tae Joon Won1, Kyeong Eun Hyung1, Ye Won Jang1, Soo Jeong Kim1, Do Ik Lee2, So-Young Park3, Kwang Woo Hwang4.
Abstract
T cells play an important role in adaptive immune responses that destroy pathogens or infected cells. Therefore, regulation of T cell activity is important in various diseases, such as autoimmune diseases, hypersensitivity, and cancer. The conjugation of small ubiquitin-related modifier (SUMO) is a post-translational protein modification that regulates activity, stability, and subcellular translocation of target proteins. In this study, CD8(+) T cells overexpressing SUMO2 showed greater proliferation and cytotoxic activity against tumor cells in the presence of IL-6 than wild-type CD8(+) T cells in vitro. These CD8(+) T cell functions were suppressed during treatment with MEK1 or PI3K-specific inhibitors. Therefore, our findings suggest that IL-6-derived signaling pathways, including the MEK1 and PI3K pathways, are upregulated by SUMO2 overexpression. However, transgenic expression of SUMO2 in T cells did not modulate Th1/2 balance. Collectively, our results showed that SUMO2-Tg promotes cytotoxic activity against tumor cells by increasing the proliferation and cytotoxicity of CD8(+) T cells.Entities:
Keywords: CD8+ T cells; Cytotoxicity; IL-6; Proliferation; SUMO2
Mesh:
Substances:
Year: 2016 PMID: 27071615 DOI: 10.1007/s12272-016-0736-6
Source DB: PubMed Journal: Arch Pharm Res ISSN: 0253-6269 Impact factor: 4.946